- Home
- IRD vs VYNE Comparison
IRD vs VYNE Comparison
Compare IRD & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- VYNE
- Stock Information
- Founded
- IRD 2018
- VYNE 2003
- Country
- IRD United States
- VYNE United States
- Employees
- IRD N/A
- VYNE N/A
- Industry
- IRD
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- IRD
- VYNE Health Care
- Exchange
- IRD NYSE
- VYNE Nasdaq
- Market Cap
- IRD 35.7M
- VYNE 35.7M
- IPO Year
- IRD N/A
- VYNE 2018
- Fundamental
- Price
- IRD $0.93
- VYNE $1.90
- Analyst Decision
- IRD Strong Buy
- VYNE Strong Buy
- Analyst Count
- IRD 1
- VYNE 2
- Target Price
- IRD $8.00
- VYNE $6.88
- AVG Volume (30 Days)
- IRD 141.6K
- VYNE 71.4K
- Earning Date
- IRD 03-25-2025
- VYNE 03-06-2025
- Dividend Yield
- IRD N/A
- VYNE N/A
- EPS Growth
- IRD N/A
- VYNE N/A
- EPS
- IRD N/A
- VYNE N/A
- Revenue
- IRD $8,381,000.00
- VYNE $501,000.00
- Revenue This Year
- IRD N/A
- VYNE N/A
- Revenue Next Year
- IRD $29.37
- VYNE $20.00
- P/E Ratio
- IRD N/A
- VYNE N/A
- Revenue Growth
- IRD N/A
- VYNE 18.16
- 52 Week Low
- IRD $0.81
- VYNE $1.57
- 52 Week High
- IRD $2.34
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- VYNE 29.17
- Support Level
- IRD N/A
- VYNE $1.84
- Resistance Level
- IRD N/A
- VYNE $2.57
- Average True Range (ATR)
- IRD 0.00
- VYNE 0.23
- MACD
- IRD 0.00
- VYNE -0.06
- Stochastic Oscillator
- IRD 0.00
- VYNE 11.92
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.